HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $3 price target.
October 24, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransCode Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $3.
The reiteration of a 'Buy' rating by a reputable analyst like Emily Bodnar from HC Wainwright & Co. is a positive signal for investors. The maintained price target of $3 also indicates the analyst's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100